Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
Passage Bio, Inc. (PASG)
Company Research
Source: GlobeNewswire
Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee Presented encouraging longer-term clinical and biomarker data from Cohort 1 in Imagine-1 study at ASGCT; interim safety and biomarker data for Cohorts 2 and 3 expected in 2H22Received IND clearance for Phase 1 clinical program of PBML04 for metachromatic leukodystrophyEnded 2Q22 with strong cash position; cash on hand to fund operations into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights. “We continue to be excited by the data emerging fro
Show less
Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.MarketBeat
- Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program [Yahoo! Finance]Yahoo! Finance
- Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship ProgramGlobeNewswire
- Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
PASG
Earnings
- 3/4/24 - Beat
PASG
Analyst Actions
- 3/5/24 - Canaccord Genuity
PASG
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- PASG's page on the SEC website